Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Successful treatment of Trichosporon asahii fungemia with isavuconazole in a patient with hematologic malignancies.

Feugray G, Krzisch D, Dehais M, Razakandrainibe R, Gargala G, Favennec L, Lepretre S, Camus V, Costa D.

Infect Drug Resist. 2019 Jul 9;12:2015-2018. doi: 10.2147/IDR.S211148. eCollection 2019.

2.

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P.

Lancet Haematol. 2019 Jul 16. pii: S2352-3026(19)30113-9. doi: 10.1016/S2352-3026(19)30113-9. [Epub ahead of print]

PMID:
31324600
3.

Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21-year-old patient: A case report and review.

Camus V, Dubois S, Thiébaut PA, Lepretre S, Lenain P, Picquenot JM, Veresezan EL, François A, Penther D, Bauer F, Jaccard A, Jardin F.

Clin Case Rep. 2019 May 7;7(6):1171-1177. doi: 10.1002/ccr3.2165. eCollection 2019 Jun.

4.

Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group.

Nudel M, Baran-Marszak F, Bossard JB, Dubois R, Dapvril H, Dupuis J, Laribi K, Bay JO, Tomowiak C, Dreyfus B, Lepretre S, Demarquette H, Wallyn F, Wemeau L, Wemeau M, Poulain S, Morschhauser F, Cymbalista F, Herbaux C.

Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15966. [Epub ahead of print] No abstract available.

PMID:
31115898
5.

Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.

Quinquenel A, Godet S, Dartigeas C, Ysebaert L, Dupuis J, Ohanyan H, Collignon A, Gilardin L, Lepretre S, Dilhuydy MS, Vignon M, de Guibert S, Dmytruk N, Durot E, Ghez D, Roos Weil D, Béné MC, Toussaint E, Merabet F, Lévy V, Delmer A, Aurran T.

Am J Hematol. 2019 Jul;94(7):E183-E185. doi: 10.1002/ajh.25480. Epub 2019 Apr 11. No abstract available.

PMID:
30945328
6.

Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.

Touzart A, Lengliné E, Latiri M, Belhocine M, Smith C, Thomas X, Spicuglia S, Puthier D, Pflumio F, Leguay T, Graux C, Chalandon Y, Huguet F, Leprêtre S, Ifrah N, Dombret H, Macintyre E, Hunault M, Boissel N, Asnafi V.

Clin Cancer Res. 2019 Apr 15;25(8):2483-2493. doi: 10.1158/1078-0432.CCR-18-1844. Epub 2019 Jan 18.

PMID:
30659025
7.

DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia.

Bond J, Touzart A, Leprêtre S, Graux C, Bargetzi M, Lhermitte L, Hypolite G, Leguay T, Hicheri Y, Guillerm G, Bilger K, Lhéritier V, Hunault M, Huguet F, Chalandon Y, Ifrah N, Macintyre E, Dombret H, Asnafi V, Boissel N.

Haematologica. 2019 Aug;104(8):1617-1625. doi: 10.3324/haematol.2018.197848. Epub 2019 Jan 17.

8.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S; on behalf of the PERLE investigators .

Leuk Lymphoma. 2019 Jun;60(6):1563-1567. doi: 10.1080/10428194.2018.1533130. Epub 2019 Jan 9. No abstract available.

PMID:
30624147
9.

Cyberlindnera jadinii (teleomorph Candida utilis) candidaemia in a patient with aplastic anaemia: a case report.

Treguier P, David M, Gargala G, Camus V, Stamatoullas A, Menard AL, Lenain P, Contentin N, Lemasle E, Lanic H, Tilly H, Jardin F, Lepretre S.

JMM Case Rep. 2018 Jul 10;5(8):e005160. doi: 10.1099/jmmcr.0.005160. eCollection 2018 Aug.

10.

Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.

Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, Sutton L, Lesty C, Merle-Béral H, Cymbalista F, Ysebaert L, Davi F, Leblond V; FILO working group.

Genes Chromosomes Cancer. 2018 Nov;57(11):533-540. doi: 10.1002/gcc.22650. Epub 2018 Sep 11.

11.

Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient.

Camus V, Dubois S, Lepretre S, Jardin F, Tilly H.

Clin Case Rep. 2018 Jun 4;6(8):1418-1421. doi: 10.1002/ccr3.1630. eCollection 2018 Aug.

12.

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort.

Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, Bertrand P, Etancelin P, Picquenot JM, Camus V, Menard AL, Lemasle E, Contentin N, Leprêtre S, Lenain P, Stamatoullas A, Lanic H, Libraire J, Vaudaux S, Pepin LF, Vera P, Tilly H, Jardin F.

Blood Cancer J. 2018 Aug 1;8(8):74. doi: 10.1038/s41408-018-0111-6.

13.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

14.

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.

Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL).

J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4.

15.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Cymbalista F, Ross-Weil D, Leprêtre S.

Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15. No abstract available.

16.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Cartron G, Letestu R, Dartigeas C, Tout M, Mahé B, Gagez AL, Ferrant E, Guiu B, Villemagne B, Letuan P, Aurran T, Orsini-Piocelle F, Banos A, Feugier P, Leblond V, de Guibert S, Tournilhac O, Dupuis J, Delmer A, Rouillé V, Ternant D, Leprêtre S.

Haematologica. 2018 Aug;103(8):e356-e359. doi: 10.3324/haematol.2017.182352. Epub 2018 Mar 8. No abstract available.

17.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

Dartigeas C, Van Den Neste E, Léger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Leprêtre S, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahé B, Laribi K, Michallet AS, Delmer A, Feugier P, Lévy V, Delépine R, Colombat P, Leblond V; CLL 2007 SA investigators; French Innovative Leukemia Organization (FILO).

Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

PMID:
29275118
18.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.

Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS.

Am J Hematol. 2018 Jan;93(1):E24-E27. doi: 10.1002/ajh.24951. Epub 2017 Nov 17. No abstract available.

19.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

Br J Haematol. 2017 Nov;179(3):439-448. doi: 10.1111/bjh.14881. Epub 2017 Aug 2.

PMID:
28770576
20.

Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.

Becker S, Vermeulin T, Cottereau AS, Boissel N, Vera P, Lepretre S.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2034-2041. doi: 10.1007/s00259-017-3776-3. Epub 2017 Jul 21.

PMID:
28733763
21.

Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.

Fontanilles M, Marguet F, Bohers É, Viailly PJ, Dubois S, Bertrand P, Camus V, Mareschal S, Ruminy P, Maingonnat C, Lepretre S, Veresezan EL, Derrey S, Tilly H, Picquenot JM, Laquerrière A, Jardin F.

Oncotarget. 2017 Jul 18;8(29):48157-48168. doi: 10.18632/oncotarget.18325.

22.

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V.

J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12.

PMID:
28605290
23.

Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators.

Lepretre S, Graux C, Touzart A, Macintyre E, Boissel N.

Exp Hematol. 2017 Jul;51:7-16. doi: 10.1016/j.exphem.2017.04.002. Epub 2017 Apr 12. Review.

PMID:
28412288
24.

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.

Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, Algrin C, Keren B, Damm F, Gabillaud C, Brunelle-Navas MN, Davi F, Merle-Béral H, Le Garff-Tavernier M, Roos-Weil D, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Lepretre S, Feugier P, Lesty C, Lejeune J, Sutton L, Landesman Y, Susin SA, Nguyen-Khac F.

Leukemia. 2017 Jul;31(7):1625-1629. doi: 10.1038/leu.2017.100. Epub 2017 Mar 27. No abstract available.

PMID:
28344316
25.

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Chaoui D, Choquet S, Sanhes L, Mahé B, Hacini M, Fitoussi O, Arkam Y, Orfeuvre H, Dilhuydy MS, Barry M, Jourdan E, Dreyfus B, Tempescul A, Leprêtre S, Bardet A, Leconte P, Maynadié M, Delmer A.

Leuk Lymphoma. 2017 Jun;58(6):1366-1375. doi: 10.1080/10428194.2016.1243673. Epub 2017 Feb 9.

PMID:
28271952
26.

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuaillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G, Apparailly F.

Haematologica. 2017 Apr;102(4):746-754. doi: 10.3324/haematol.2016.153189. Epub 2017 Jan 25.

27.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H.

Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.

28.

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Meunier G, Ysebaert L, Nguyen-Thi PL, Lepretre S, Quinquenel A, Dupuis J, Lemal R, Aurran T, Tomowiak C, Cymbalista F, Dilhuydy MS, Brion A, Morel P, Cazin B, Leblond V, Cartron G, Ré D, Béné MC, Michallet AS, Feugier P.

Hematol Oncol. 2017 Dec;35(4):671-678. doi: 10.1002/hon.2370. Epub 2016 Nov 22.

PMID:
27878835
29.

Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.

Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, Lepretre S, Re D, Fahri J, Michallet AS, Ysebaert L, Lemal R, Lamy T, Delarue R, Troussard X, Cymbalista F, Levy V, Dietrich PY, Leblond V, Aurran-Schleinitz T.

Br J Haematol. 2017 Jan;176(1):37-49. doi: 10.1111/bjh.14387. Epub 2016 Nov 11.

PMID:
27858991
30.

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.

Clin Pharmacokinet. 2017 Jun;56(6):635-647. doi: 10.1007/s40262-016-0470-8.

PMID:
27783363
31.

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.

Gagez AL, Tuaillon E, Cezar R, Dartigeas C, Mahé B, Letestu R, Maisonneuve H, Gouilleux-Gruart V, Bollore K, Ferrant E, Aurran T, Feugier P, Leprêtre S, Cartron G.

Blood Cancer J. 2016 Jan 22;6:e389. doi: 10.1038/bcj.2015.115. No abstract available.

32.

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.

Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H.

J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385. Epub 2015 Dec 7.

33.

Spontaneous remission in three cases of AML M5 with NPM1 mutation.

Camus V, Etancelin P, Jardin F, Lenain P, Contentin N, Daliphard S, Buchonnet G, Lemasle E, Lanic H, Leprêtre S, Penther D, Dubois S, Tilly H, Bastard C, Stamatoullas A.

Clin Case Rep. 2015 Nov;3(11):955-9. doi: 10.1002/ccr3.408. Epub 2015 Oct 21.

34.

Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.

Stamatoullas A, Rezine I, Mareschal S, Ménard AL, Lanic H, David M, Daliphard S, Penther D, Lemasle E, Cassuto O, Lenain P, Contentin N, Lepretre S, Jardin F, Bastard C, Tilly H.

Leuk Lymphoma. 2016;57(6):1491-3. doi: 10.3109/10428194.2015.1101096. Epub 2015 Nov 16. No abstract available.

PMID:
26430832
35.

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

Simon L, Fitsiori A, Lemal R, Dupuis J, Carpentier B, Boudin L, Corby A, Aurran-Schleinitz T, Gastaud L, Talbot A, Leprêtre S, Mahe B, Payet C, Soussain C, Bonnet C, Vincent L, Lissandre S, Herbrecht R, Kremer S, Leblond V, Fornecker LM.

Haematologica. 2015 Dec;100(12):1587-94. doi: 10.3324/haematol.2015.133744. Epub 2015 Sep 18. Review.

36.

Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.

Lepretre S, Dartigeas C, Feugier P, Marty M, Salles G.

Leuk Lymphoma. 2016;57(4):852-65. doi: 10.3109/10428194.2015.1085528. Epub 2015 Oct 8. Review.

PMID:
26308278
37.

Human herpesvirus-6 acute limbic encephalitis after unrelated umbilical cord blood transplantation successfully treated with ganciclovir.

Camus V, Bouwyn JP, Chamseddine A, Lenain P, Ahtoy P, Stamatoullas A, Lanic H, Lemasle E, Contentin N, Cassuto O, Leprêtre S, Dubois S, Tilly H, Jardin F.

Bone Marrow Transplant. 2015 Oct;50(10):1385-7. doi: 10.1038/bmt.2015.159. Epub 2015 Jul 6. No abstract available.

PMID:
26146808
38.

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V.

Leuk Lymphoma. 2016 Feb;57(2):328-334. doi: 10.3109/10428194.2015.1063139. Epub 2015 Sep 28.

PMID:
26140301
39.

Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia.

Ruminy P, Marchand V, Buchbinder N, Larson T, Joly B, Penther D, Lemasle E, Lepretre S, Angot E, Mareschal S, Viailly PJ, Dubois S, Clatot F, Viennot M, Bohers E, Rizzo D, Cornic M, Bertrand P, Girod C, Camus V, Etancelin P, Buchonnet G, Schneider P, Picquenot JM, Vannier JP, Bastard C, Tilly H, Jardin F.

Leukemia. 2016 Mar;30(3):757-60. doi: 10.1038/leu.2015.177. Epub 2015 Jul 3. No abstract available.

PMID:
26139430
40.

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Béné MC, Liens D, Godfrin Y, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Am J Hematol. 2015 Sep;90(9):811-8. doi: 10.1002/ajh.24093.

41.

¹⁸F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies.

Camus V, Edet-Sanson A, Bubenheim M, Hitzel A, Becker S, David M, Stamatoullas A, Lenain P, Jardin F, Contentin N, Fontoura ML, Cardinael N, Vaudaux S, Dubois S, Tilly H, Vera P, Leprêtre S.

Anticancer Res. 2015 May;35(5):2999-3005.

PMID:
25964587
42.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2015 Jun 11;125(24):3711-9. doi: 10.1182/blood-2015-02-627935. Epub 2015 Apr 15. Erratum in: Blood. 2015 Sep 3;126(10):1261.

43.

The spectrum of kidney pathology in B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma: a 25-year multicenter experience.

Poitou-Verkinder AL, Francois A, Drieux F, Lepretre S, Legallicier B, Moulin B, Godin M, Guerrot D.

PLoS One. 2015 Mar 26;10(3):e0119156. doi: 10.1371/journal.pone.0119156. eCollection 2015.

44.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.

Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L.

Am J Hematol. 2015 Jun;90(6):511-4. doi: 10.1002/ajh.23999. Epub 2015 Apr 1.

45.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N.

Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24.

46.

Invasive aspergillosis in neutropenic patients during hospital renovation: effectiveness of mechanical preventive measures in a prospective cohort of 438 patients.

Loschi M, Thill C, Gray C, David M, Bagatha MF, Chamseddine A, Contentin N, Jardin F, Lanic H, Lemasle E, Lenain P, Stamatoullas A, Tilly H, Lepretre S.

Mycopathologia. 2015 Jun;179(5-6):337-45. doi: 10.1007/s11046-015-9865-6. Epub 2015 Jan 31.

PMID:
25637199
47.

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M.

Leukemia. 2015 Jul;29(7):1602-4. doi: 10.1038/leu.2015.14. Epub 2015 Jan 30. No abstract available.

PMID:
25634683
48.

Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study.

Durot E, Michallet AS, Leprêtre S, Le QH, Leblond V, Delmer A.

Eur J Haematol. 2015 Aug;95(2):160-7. doi: 10.1111/ejh.12474. Epub 2015 Jan 21.

PMID:
25359318
49.

Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.

Dupuis J, Brice P, François S, Ysebaert L, de Guibert S, Levy V, Leprêtre S, Choquet S, Dilhuydy MS, Fornecker L, Morel V, Tempescul A.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):e43-6. doi: 10.1016/j.clml.2014.07.013. Epub 2014 Aug 1.

PMID:
25193089
50.

Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors.

Mendes-da-Cruz DA, Brignier AC, Asnafi V, Baleydier F, Messias CV, Lepelletier Y, Bedjaoui N, Renand A, Smaniotto S, Canioni D, Milpied P, Balabanian K, Bousso P, Leprêtre S, Bertrand Y, Dombret H, Ifrah N, Dardenne M, Macintyre E, Savino W, Hermine O.

PLoS One. 2014 Jul 28;9(7):e103405. doi: 10.1371/journal.pone.0103405. eCollection 2014.

Supplemental Content

Loading ...
Support Center